Immunology of VIP: a review and therapeutical perspectives. - Wikidata - awgldk - TriplyDB

Immunology of VIP: a review and therapeutical perspectives.

Immunology of VIP: a review and therapeutical perspectives.

http://www.wikidata.org/entity/Q34137548

about

Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis.The Neuromodulation of the Intestinal Immune System and Its Relevance in Inflammatory Bowel Disease VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins Neuroendocrine immunoregulation in multiple sclerosis Antioxidant and anti-apoptotic activity of vasoactive intestinal peptide (VIP) against 6-hydroxy dopamine toxicity in the rat corpus striatum Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor.Therapeutic potential of vasoactive intestinal peptide and its receptors in neurological disorders.VIP deficient mice exhibit resistance to lipopolysaccharide induced endotoxemia with an intrinsic defect in proinflammatory cellular responses.VPAC2 (vasoactive intestinal peptide receptor type 2) receptor deficient mice develop exacerbated experimental autoimmune encephalomyelitis with increased Th1/Th17 and reduced Th2/Treg responses.Microglial VPAC1R mediates a novel mechanism of neuroimmune-modulation of hippocampal precursor cells via IL-4 release.Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis.Inhibition of MHC II gene transcription by nitric oxide and antioxidants.Clinical Relevance of VPAC1 Receptor Expression in Early Arthritis: Association with IL-6 and Disease Activity VIP-grafted sterically stabilized phospholipid nanomicellar 17-allylamino-17-demethoxy geldanamycin: a novel targeted nanomedicine for breast cancer VIP modulates the pro-inflammatory maternal response, inducing tolerance to trophoblast cells.Differential activation of enkephalin, galanin, somatostatin, NPY, and VIP neuropeptide production by stimulators of protein kinases A and C in neuroendocrine chromaffin cells Inhibition of interferon (IFN) gamma-induced Jak-STAT1 activation in microglia by vasoactive intestinal peptide: inhibitory effect on CD40, IFN-induced protein-10, and inducible nitric-oxide synthase expression.Defects in the vasoactive intestinal peptide (VIP)/VPAC system during early stages of the placental-maternal leucocyte interaction impair the maternal tolerogenic response.Th17 polarization of memory Th cells in early arthritis: the vasoactive intestinal peptide effect.Dual bronchodilatory and pulmonary anti-inflammatory activity of RO5024118, a novel agonist at vasoactive intestinal peptide VPAC2 receptors.VIP down-regulates TLR4 expression and TLR4-mediated chemokine production in human rheumatoid synovial fibroblasts.Vasoactive intestinal peptide enhances striatal plasticity and prevents dopaminergic cell loss in Parkinsonian rats.Prolonged acetylsalicylic-acid-supplementation-induced gastritis affects the chemical coding of the stomach innervating vagal efferent neurons in the porcine dorsal motor vagal nucleus (DMX).Effect of VIP on the balance between cytokines and master regulators of activated helper T cells.Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia.Localization and chemical coding of the dorsal motor vagal nucleus (DMX) neurons projecting to the porcine stomach prepyloric area in the physiological state and after stomach partial resection.Vasoactive intestinal peptide impairs leucocyte migration but fails to modify experimental murine colitis.Time-course expression of Toll-like receptors 2 and 4 in inflammatory bowel disease and homeostatic effect of VIP.cDNA array analysis of cytokines, chemokines, and receptors involved in the development of TNBS-induced colitis: homeostatic role of VIP.Neuroendocrine cells derived chemokine vasoactive intestinal polypeptide (VIP) in allergic diseases.Preferential expression of the vasoactive intestinal peptide (VIP) receptor VPAC1 in human cord blood-derived CD34+CD38- cells: possible role of VIP as a growth-promoting factor for hematopoietic stem/progenitor cells.Vasoactive intestinal peptide gene polymorphisms, associated with its serum levels, predict treatment requirements in early rheumatoid arthritis.Mapping the CRF-urocortins system in human osteoarthritic and rheumatoid synovial fibroblasts: effect of vasoactive intestinal peptide.Therapeutic efficacy of vasoactive intestinal peptide in escherichia coli lipopolysaccharide-induced experimental periodontitis in rats.Colonic levels of vasoactive intestinal peptide decrease during infection and exogenous VIP protects epithelial mitochondria against the negative effects of IFNγ and TNFα induced during Citrobacter rodentium infection

P2860

Q24812326-706CC5C6-9ED2-463A-A14A-A9C8CC9032C6 Q26774660-DFA9157D-C52C-4E3B-A5FB-687C1338808A Q26827172-C1335626-E97F-4C30-97F3-BEBFDAB5E5F2 Q26864449-D958D001-2618-4850-ADC6-1B1D287F6477 Q28566901-E4E11CE0-25C8-4B5B-B020-4740E2A5894F Q33894893-F7CDE75C-1187-49D3-A378-CA8BF3F87164 Q34259060-8303187E-5430-465B-AC6B-6FDD22648197 Q34277527-D5C3BE52-46FB-4BBE-BCD5-EBDC63D92DDB Q34765538-1F16738D-B0FC-4EDB-B91B-CB1A6678F035 Q35107951-D96BA6AD-7974-4A77-A186-FFF2467355CA Q35295564-EE02589B-E5C6-49E4-A137-63D5C979EB09 Q35699343-43D68867-2CA9-437E-B870-C0B9A69C601A Q35924965-D6D1D0AC-ABC2-431F-B20D-E06F2A2BA3C7 Q37075370-CDEE9208-FE14-46CE-A419-82D9529DA1DB Q37230862-7B850433-D447-49AF-B825-9FEF4155AB92 Q37350121-EC971DAB-3755-4487-A00E-9A8527136276 Q38354522-C6015B10-7E1F-40D1-A73C-B883B36BAE63 Q39250380-6A288CA2-78BA-4183-9F8D-7551F1994C8D Q40957920-04F0FAD9-2173-46E4-9078-36DC3703A798 Q41121832-E6CC8AC8-41AB-4FD9-8018-2B00E198005E Q42487146-08F4FF46-7806-4DCD-9A12-C5F4AB24C4FB Q42505593-DDDD3E79-2800-4B80-AFE9-F52162216DE2 Q42867139-BFB75A7C-9090-4495-968A-F5EECA4C4B63 Q43554142-FAEDFCF0-9B19-472F-9C00-C62718CC2F7E Q44060393-E83C781D-303D-48EA-BF39-92F7DCFCAA5E Q44795267-82853075-B146-4F4A-A550-9573D330E145 Q45282194-0EEB3BA4-0A87-49E6-829B-D1802198F62A Q46460985-BC20D9F2-DB02-451A-9B2F-E6AE6A394D59 Q46562251-8326A3B5-0D53-43D7-8C85-2A9EB77C5B7F Q47921833-436A6601-C92B-49E3-B96D-AE9BF2688AFE Q48004175-D7C31C19-F54B-496E-A185-C6E12EBFC470 Q48120810-6DB62FD7-5F8C-483B-A351-A28D6E43909C Q54385451-E378F534-47C6-41D6-A604-8608D81840BF Q54397909-BD33117B-A231-468D-A346-4F0C78605A60 Q58699103-3CA8CB1C-8D45-4548-A424-2AFE15FD2643

P2860

Immunology of VIP: a review and therapeutical perspectives.

http://www.wikidata.org/entity/Q34137548

description

2001 nî lūn-bûn

@nan

2001 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年学术文章

@wuu

2001年学术文章

@zh-cn

2001年学术文章

@zh-hans

2001年学术文章

@zh-my

2001年学术文章

@zh-sg

2001年學術文章

@yue

name

Immunology of VIP: a review and therapeutical perspectives.

@ast

Immunology of VIP: a review and therapeutical perspectives.

@en

Immunology of VIP: a review and therapeutical perspectives.

@nl

type

label

Immunology of VIP: a review and therapeutical perspectives.

@ast

Immunology of VIP: a review and therapeutical perspectives.

@en

Immunology of VIP: a review and therapeutical perspectives.

@nl

prefLabel

Immunology of VIP: a review and therapeutical perspectives.

@ast

Immunology of VIP: a review and therapeutical perspectives.

@en

Immunology of VIP: a review and therapeutical perspectives.

@nl

P1433

Q34137548-DC7FF411-6250-4C29-BE87-C631CBF74080

P1476

Q34137548-34EEAAF6-1488-488A-BE30-475958107A30

P2093

Q34137548-82672EBE-2EE6-49E7-91DD-A69F6DAB817F

Q34137548-8D00DC59-9919-4D81-92D3-ED76A4B159CD

Q34137548-C3ECB7E4-0785-4618-8698-BDBB5CAC0DC4

P304

Q34137548-8A153DC6-14ED-45DB-9E0E-B1A43EB02556

P31

Q34137548-73A747EA-6131-456B-AC94-FA610A52ADDC

P356

Q34137548-A77842B3-5436-49F5-B0D0-D552AE138E37

P433

Q34137548-568778F9-C2FE-40C1-AE7A-0AA8004B22A3

P478

Q34137548-751C6118-EEC9-4ACE-98AA-C7FDA9C36CDA

P50

Q34137548-1087B75D-FBB4-4D05-87BF-8AF0AB49F597

Q34137548-D2DF5A9B-36E1-41EF-8911-6EFB138CE70A

P577

Q34137548-B66EE3A5-DB5F-4D57-AA4E-9471CF040FCA

P5875

Q34137548-1B9910B5-6A59-4061-8897-E1F8A4F4AA02

P698

Q34137548-03C51DF3-0D01-4168-A03F-F4AAADF33B28

P356

1381612013398374

P1433

Current Pharmaceutical Design

P1476

Immunology of VIP: a review and therapeutical perspectives

@en

P2093

C Martinez

http://www.w3.org/2001/XMLSchema#string

J Leceta

http://www.w3.org/2001/XMLSchema#string

R P Gomariz

http://www.w3.org/2001/XMLSchema#string

P304

89-111

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2174/1381612013398374

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

P577

2001-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12157145

http://www.w3.org/2001/XMLSchema#string

P698

11172702

http://www.w3.org/2001/XMLSchema#string